Table of Contents
Chemotherapy Research and Practice
Volume 2011 (2011), Article ID 213848, 7 pages
http://dx.doi.org/10.1155/2011/213848
Research Article

Optimizing Liposomal Cisplatin Efficacy through Membrane Composition Manipulations

Department of Preformulation, Celator Pharmaceuticals Corp., 1779 West 75th Avenue, Vancouver, BC, Canada V6P 6P2

Received 27 August 2010; Revised 7 December 2010; Accepted 17 December 2010

Academic Editor: G. J. Peters

Copyright © 2011 Natalia Zisman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. T. Daley-Yates and D. C. H. McBrien, “Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumor activity of cisplatin,” Biochemical Pharmacology, vol. 33, no. 19, pp. 3063–3070, 1984. View at Publisher · View at Google Scholar · View at Scopus
  2. S. D. Fosså, S. P. Stenning, A. Gerl et al., “Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours,” British Journal of Cancer, vol. 80, no. 9, pp. 1392–1399, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. D. K. Armstrong, B. Bundy, L. Wenzel et al., “Intraperitoneal cisplatin and paclitaxel in ovarian cancer,” The New England Journal of Medicine, vol. 354, no. 1, pp. 34–43, 2006. View at Publisher · View at Google Scholar
  4. A. L. Pinto and S. J. Lippard, “Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA,” Biochimica et Biophysica Acta, vol. 780, no. 3, pp. 167–180, 1984. View at Publisher · View at Google Scholar · View at Scopus
  5. M. A. Fuertes, C. Alonso, and J. M. Pérez, “Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance,” Chemical Reviews, vol. 103, no. 3, pp. 645–662, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. M. A. Fuertes, J. Castilla, C. Alonso, and J. M. Pérez, “Cisplatin biochemical mechanism of action: from cytotoxity to induction of cell death through interconnections between apoptotic and necrotic pathways,” Current Medicinal Chemistry, vol. 10, no. 3, pp. 257–266, 2003. View at Google Scholar
  7. I. H. Krakoff, “Nephrotoxicity of cis-dichlorodiammineplatinum(II),” Cancer Treatment Reports, vol. 63, no. 9-10, pp. 1523–1525, 1979. View at Google Scholar · View at Scopus
  8. P. P. Coradini, L. Cigana, S. G. A. Selistre, L. S. Rosito, and A. L. Brunetto, “Ototoxicity from cisplatin therapy in childhood cancer,” Journal of Pediatric Hematology/Oncology, vol. 29, no. 6, pp. 355–360, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. I. Arany and R. L. Safirstein, “Cisplatin nephrotoxicity,” Seminars in Nephrology, vol. 23, no. 5, pp. 460–464, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. R. K. Potkul, J. Gondal, P. Bitterman, K. L. Dretchen, and A. Rahman, “Toxicities in rats with free versus liposomal encapsulated cisplatin,” American Journal of Obstetrics and Gynecology, vol. 164, no. 2, pp. 652–658, 1991. View at Google Scholar · View at Scopus
  11. P. A. Steerenberg, G. Storm, G. de Groot et al., “Liposomes as drug carrier system for cis-diamminedichloroplatinum(II): II. Antitumor activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution,” Cancer Chemotherapy and Pharmacology, vol. 21, no. 4, pp. 299–307, 1988. View at Google Scholar · View at Scopus
  12. S. C. White, P. Lorigan, G. P. Margison et al., “Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer,” British Journal of Cancer, vol. 95, no. 7, pp. 822–828, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Boulikas, “Molecular mechanisms of cisplatin and its liposomally encapuslated form, LipoplatinTM as a chemotherapy and antiangiogenesis drug,” Cancer Therapy, vol. 5, pp. 351–376, 2007. View at Google Scholar
  14. F. Lazarioti and T. Boulikas, “Diagnostic and therapeutic efficacy of imaging modalities in non-small cell lung cancer (BSCLC):experience from a phase III clinical study using tumor targeted Lipoplatin nanoparticles,” Cancer Therapy, vol. 6, pp. 629–646, 2008. View at Google Scholar
  15. D. M. Vail, I. D. Kurzman, P. C. Glawe et al., “STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial,” Cancer Chemotherapy and Pharmacology, vol. 50, no. 2, pp. 131–136, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. M. S. Newman, G. T. Colbern, P. K. Working, C. Engbers, and M. A. Amantea, “Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice,” Cancer Chemotherapy and Pharmacology, vol. 43, no. 1, pp. 1–7, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. W. C. Zamboni, A. C. Gervais, M. J. Egorin et al., “Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma,” Cancer Chemotherapy and Pharmacology, vol. 53, no. 4, pp. 329–336, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Boulikas, “Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts,” Oncology Reports, vol. 12, no. 1, pp. 3–12, 2004. View at Google Scholar · View at Scopus
  19. T. Boulikas, A. Pantos, E. Bellis, and P. Christofis, “Designing platinum compounds in cancer: structures and mechanisms,” Cancer Therapy, vol. 5, pp. 537–583, 2007. View at Google Scholar
  20. P. G. Tardi, R. C. Gallagher, S. Johnstone et al., “Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo,” Biochimica et Biophysica Acta, vol. 1768, no. 3, pp. 678–687, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Tardi, S. Johnstone, N. Harasym et al., “In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy,” Leukemia Research, vol. 33, no. 1, pp. 129–139, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. P. G. Tardi, N. Dos Santos, T. O. Harasym et al., “Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo,” Molecular Cancer Therapeutics, vol. 8, no. 8, pp. 2266–2275, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. L. D. Mayer, M. B. Bally, H. Loughrey, D. Masin, and P. R. Cullis, “Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors,” Cancer Research, vol. 50, no. 3, pp. 575–579, 1990. View at Google Scholar · View at Scopus